Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, announced ELIMINATE-B results as of the data cutoff of July 28, 2025. Data include completed Cohort 1 (dosed at 0.2 mg/kg), the lowest dose level of the ELIMINATE-B trial, and initial safety data from Cohort 2 (dosed at 0.4 mg/kg). The ELIMINATE-B trial is designed
Related Questions
What are the implications of the Phase 1 safety and efficacy results for the timeline to next trial phases and potential FDA approval?
Are there any hedging or short‑position opportunities based on the disclosed data?
How will the trial results affect Precision BioSciences' projected revenue and cash burn?
What are the potential regulatory pathways and milestones post‑Phase 1 for PBGENE‑HBV?
Is there any disclosed data on viral load reduction or functional cure rates for Cohort 1?
How might this affect the competitive landscape with other CRISPR/Cas‑based hepatitis B candidates?
How does the safety profile compare to existing HBV therapies and competing gene‑editing programs?
Will the data trigger any partnership or licensing discussions with biotech or pharma companies?
Does the release provide any insight into manufacturing scalability and cost of goods for the therapy?
What are the dosing plans for subsequent cohorts and expected enrollment numbers?
How likely is the market to react to this news in terms of price movement, volume, and volatility?